What does Acepodia, Inc. do?

Acepodia, Inc. (6976.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6976.TWO's market cap?

Acepodia, Inc. (6976.TWO) has a market capitalization of approximately $6.82 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6976.TWO pay a dividend?

No — Acepodia, Inc. (6976.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6976.TWO profitable?

Acepodia, Inc. (6976.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6976.TWO

Acepodia, Inc.

TWO·Biotechnology · Healthcare

NT$11.75NT$0.30−2.49%

Market capNT$6.82B·Market closed·Aug 26 6:57 AM UTC

Price Chart

NT$11.75−NT$0.30 (−2.49%)today

−70.73%CAGR −33.16%

Select date range

FromTo

Aug 8, 2023Aug 8, 2023 → Aug 26, 2026· 3.0 yrsAug 26, 2026

Key Metrics

6976.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$185.00K

Net Income−NT$754.40M

Net Margin−407,784.3%

Operating Cash Flow−NT$707.27M

Capital ExpendituresNT$71.31M

Free Cash Flow−NT$778.57M

Return on Equity−13.9%

Return on Invested Capital−9.0%

Net CashNT$3.54B

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6976.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6976.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6976.TWO and 80,000+ other tickers.

About Acepodia, Inc.

Acepodia, Inc. is an advanced-stage biotechnology firm focused on pioneering cell-based treatments. The company utilizes its distinctive Antibody Cell Conjugation (ACC) platform technology to innovate therapeutic approaches and address critical unmet needs in oncology. Through this proprietary method, Acepodia engineers novel ACE therapies by precisely attaching tumor-specific antibodies to its specialized immune cells, such as gamma delta 2 T cells. Established in 2017, the company's corporate headquarters are situated in Grand Cayman, Cayman Islands.

CEO: Sonny Hsiao
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 20
Website: www.acepodia.com

Peers

Medeon Biodesign, Inc.

Cap

NT$6.9B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6976.TWO

What does Acepodia, Inc. do?: Acepodia, Inc. (6976.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6976.TWO's market cap?: Acepodia, Inc. (6976.TWO) has a market capitalization of approximately $6.82 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6976.TWO pay a dividend?: No — Acepodia, Inc. (6976.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6976.TWO profitable?: Acepodia, Inc. (6976.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.